Approximately 10 years after vaccination with the recombinant zoster vaccine (RZV), an interim analysis of this follow-up study of the ZOE-50/70 trials demonstrated that efficacy against herpes zoster remained high. Moreover, the safety profile remained clinically acceptable, suggesting that the clinical benefit of the RZV in ≥50-year-olds is sustained up to 10 years.
Keywords: adjuvanted recombinant zoster vaccine; immune response persistence; long-term efficacy; long-term safety.
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.